PDCD1 and non-small cell lung carcinoma: The emergence of immune checkpoint inhibitors (ICIs), such as those targeting programmed cell death 1 (PD-1) or its ligand (PD-L1), has transformed the treatment and management of advanced non-small cell lung cancer (NSCLC), which constitutes most lung cancers1.